Unusually small intravenous doses of amphotericin B (10 to 355 mg given over 4 to 18 days) were effective in the treatment of 14 selected patients with severe and disabling Candida infections. These included nine with mucocutaneous infections in whom vigorous topical antifungal therapy had failed. Five other patients had systemic disease that had not responded to the removal of intravenous catheters or discontinuation of antibiotics. Follow-up over 2 to 24 months showed no recurrences. No toxicity was encountered except in the recipient of the largest dose, who had transient azotemia. Our limited experience suggests the efficacy of amphotericin B in small nontoxic doses in the treatment of mucocutaneous and systemic Candida infections, excluding meningitis and endocarditis.
Medoff G, Dismukes WE, Meade RH, Moses JM. A New Therapeutic Approach to Candida Infections: A Preliminary Report. Arch Intern Med. 1972;130(2):241–245. doi:10.1001/archinte.1972.03650020067013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: